Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002536615 | SCV002966441 | pathogenic | not provided | 2022-05-05 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 627443). This premature translational stop signal has been observed in individual(s) with clinical features of ERCC3-related conditions (PMID: 31541171). This variant is present in population databases (rs138385061, gnomAD 0.004%). This sequence change creates a premature translational stop signal (p.Arg195*) in the ERCC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ERCC3 are known to be pathogenic (PMID: 16947863). |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004800578 | SCV005422943 | pathogenic | Xeroderma pigmentosum | 2024-10-08 | criteria provided, single submitter | clinical testing | Variant summary: ERCC3 c.583C>T (p.Arg195X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 1.6e-05 in 251470 control chromosomes. c.583C>T has been reported in the literature in individuals affected with ERCC3-related conditions (e.g. Yuan_2020). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 31541171). ClinVar contains an entry for this variant (Variation ID: 627443). Based on the evidence outlined above, the variant was classified as pathogenic. |
Genetic Testing Center for Deafness, |
RCV000770819 | SCV000902307 | pathogenic | Xeroderma pigmentosum group B | 2019-02-26 | no assertion criteria provided | case-control |